The goal of the trial was to reduce levels of phenylalanine, an amino acid, in the blood. Patients with the inherited metabolic disorder cannot break down phenylalanine on their own, causing a build-up of the acid, which often leads to memory and neurological issues.
Tag Archive for: Primary endpoints
When Roche announced that gantenerumab failed to meet the primary endpoint in two Phase III studies, several of its competitors saw their stocks rise – including Biogen and Eisai.
New York-based Axsome Therapeutics published results from the pivotal Phase III Gemini trial of AXS-05 (dextromethorphan-bupropion) in major depressive disorder (MDD).
